Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -147% Improvement Relative Risk c19hcq.org Barbosa et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 63 patients in the USA Higher mortality with HCQ (not stat. sig., p=0.58) Barbosa et al., Preprint Favors HCQ Favors control
Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study
Barbosa et al., Preprint (Preprint)
Barbosa et al., Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative.., Preprint (Preprint)
Apr 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small retrospective study with 63 patients (32 treated with HCQ), showing no effectiveness, however the baseline state of each arm significantly differs.
This preprint was submitted to NEJM but has not been published several months later. This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 147.0% higher, RR 2.47, p = 0.58, treatment 2 of 17 (11.8%), control 1 of 21 (4.8%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Barbosa et al., 12 Apr 2020, retrospective, USA, preprint, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Submitted to the New England Journal of Medicine Please review the Supplemental Files folder to review documents not compiled in the PDF. Co Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: A Quasi-Randomized Comparative Study nf Journal: New England Journal of Medicine Manuscript ID 20-08882 ide Article Type: Rapid Review Date Submitted by the 04-Apr-2020 Author: ial nt Complete List of Authors: Barbosa, Joshua; Wayne State University School of Medicine; Sinai Grace Hospital Kaitis, Daniel; Henry Ford Hospital Freedman, Ryan; Wayne State University School of Medicine Le, Kim; Henry Ford Hospital Lin, Xihui; Wayne State University School of Medicine, w vie Re or :F Background: Off-label use of hydroxychloroquine in the SARS-CoV-2 positive population has become widespread with only empirical evidence on its efficacy. This study addresses the efficacy of hydroxychloroquine on serological and supportive care measures in a hospitalized population. Methods: Consecutive adult subjects admitted for viral pneumonia secondary to SARS-CoV-2 (by polymerase chain reaction) during the last two weeks of March, 2020 were included. Those that were started on hydroxychloroquine and supportive care were compared to supportive care alone. The primary end points were effect of hydroxychloroquine usage on the need to escalate respiratory support, change in lymphocyte count, and change in neutrophil-to-lymphocyte ratio. Results: A total of 63 patients were included with 32 in the hydroxychloroquine arm. Hydroxychloroquine administration was Abstract: associated with a need for escalation of respiratory support level compared to those that did not receive hydroxychloroquine at 5 days (p=0.013). The same findings were observed in a baseline-matched subgroup analysis. Absolute lymphocyte change in the hydroxychloroquine group was no different than supportive care alone (p=0.413). Hydroxychloroquine use trended towards worsening neutrophil-to-lymphocyte ratio compared to supportive care alone (+9.59 vs +1.58, p=0.51) as well as a higher risk for intubation (p=0.051). Conclusion: Hydroxychloroquine administration to the hospitalized SARSCoV-2 positive population was associated with an increased need for escalation of respiratory support. There were no benefits of hydroxychloroquine on mortality, lymphopenia, or neutrophil-tolymphocyte ratio improvement. Confidential: Destroy when review is complete. Page 1 of 13 w vie Re or :F ial nt ide nf Co 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Submitted to the New England Journal of Medicine Confidential: Destroy when review is complete. Submitted to the New England Journal of Medicine Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: A QuasiRandomized Comparative Study Joshua Barbosa, MD1,2; Daniel Kaitis, MD3; Ryan Freedman, MD1; Kim Le, MD3; Xihui Lin, MD1 1Ophthalmology, 2Sinai Kresge Eye Institute & Wayne State University Detroit, Michigan, USA Grace Hospital, Detroit, Michigan, USA Co 3Department of Ophthalmology, Henry Ford Hospital System, Detroit, Michigan, USA nf Corresponding Author: Dr. Xihui Lin Address: 4717 St. Antoine, Detroit, MI, 48201, USA ide Telephone Number: 313-577-8900 Email: xihui.lin@wayne.edu ial nt Conflict of Interest: None of the authors have any conflicts of interest..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit